XML 46 R36.htm IDEA: XBRL DOCUMENT v3.25.1
Collaboration, License, and Other Agreements - Amounts Recognized In Statement of Operations with Sanofi (Details) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Disaggregation of Revenue [Line Items]    
Revenues $ 3,028.7 $ 3,145.0
Sanofi Collaboration Agreement, Antibody | Collaboration revenue | Regeneron's share of profits    
Disaggregation of Revenue [Line Items]    
Revenues 1,018.2 804.0
Sanofi Collaboration Agreement, Antibody | Collaboration revenue | Reimbursement for manufacturing of commercial supplies    
Disaggregation of Revenue [Line Items]    
Revenues 165.0 105.8
Sanofi Collaboration Agreement, Antibody | (R&D expense) | Regeneron's obligation for its share of Sanofi R&D expenses, net of reimbursement of R&D expenses    
Disaggregation of Revenue [Line Items]    
Revenues (15.5) (18.6)
Sanofi Collaboration Agreement, Antibody | Reduction of SG&A expense | Reimbursement of commercialization-related expenses    
Disaggregation of Revenue [Line Items]    
Revenues $ 159.2 $ 139.5